An artificial intelligence (AI) tool can accurately and consistently classify breast density on mammograms, according to a study in Radiology: Artificial Intelligence. Breast density reflects the amount of fibroglandular… read more.
For primary care teams, keeping up-to-date with developments and current best practice is the key to expediting ovarian cancer diagnosis, according to Dr Sharon Tate, Head of Primary… read more.
University of Queensland researchers have demonstrated a genetic link between endometriosis and ovarian cancer subtypes enabling them to identify potential drug targets for therapy and increasing the understanding… read more.
It is a complete myth that ovarian cancer is a silent killer – even early-stage disease causes symptoms and knowing what they are is key to early treatment,… read more.
Two thirds of UK women with ovarian cancer are diagnosed late when the cancer has spread and is difficult to treat. IMI spoke to Dr Sharon Tate, Head… read more.
Depression and other mental health outcomes are similar for men choosing different options for initial treatment of localized prostate cancer, reports a study in The Journal of Urology®, an… read more.
March is ovarian cancer awareness month and 8th March is international women’s day – a good day to call for greater awareness, early diagnosis and prompt treatment of… read more.
No fewer than 11 women die of ovarian cancer every day in the UK, equivalent to more than 4000 per annum.1 About 7,500 women are diagnosed with ovarian… read more.
NICE (UK): Keytruda (pembrolizumab), from Merck Inc. with carboplatin and paclitaxel is recommended as an option for untreated metastatic squamous non-small-cell lung cancer (NSCLC) in adults, only if… read more.
Sandoz has announced the launch of generic oncology medicine lenalidomide, indicated for several haemato-oncology conditions as recommended by the latest European Society for Medical Oncology (ESMO) guidelines. The… read more.
Patients treated for Merkel cell carcinoma (MCC) face a five-year recurrence rate of 40% — markedly higher than the recurrence rates for cand other skin cancers, according to… read more.
Researchers from a phase 3 clinical trial report that addition of the androgen-receptor inhibitor darolutamide to androgen-deprivation therapy and chemotherapy significantly prolongs the survival of men with metastatic,… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
